title: Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia.
authors.affiliation: Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, UK.
authors.forename: Toby A
authors.initials: TA
authors.lastname: Eyre
authors.affiliation: Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, City Campus, Nottingham, UK.
authors.forename: Christopher P
authors.initials: CP
authors.lastname: Fox
authors.affiliation: Department of Haematology & Stem Cell Transplantation, Birmingham Heartlands Hospital, Birmingham, UK.
authors.forename: Paneesha
authors.initials: P
authors.lastname: Shankara
authors.affiliation: Department of Clinical Haematology, The Rotherham NHS Foundation Trust, Rotherham, South Yorkshire, UK.
authors.forename: Richard
authors.initials: R
authors.lastname: Went
authors.affiliation: Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, UK.|NIHR BRC Oxford Molecular Diagnostic Centre, Oxford University Hospitals NHS Trust and Department of Oncology, University of Oxford, John Radcliffe Hospital, Oxford, UK.|Department of Oncology, University of Oxford, Oxford, UK.
authors.forename: Anna H
authors.initials: AH
authors.lastname: Schuh
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D015897:Comorbidity; D014644:Genetic Variation; D006801:Humans; D054403:Leukemia, Prolymphocytic, B-Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D010641:Phenotype; D011687:Purines / Q000008:administration & dosage; D052999:Quinazolinones / Q000008:administration & dosage; D000069283:Rituximab / Q000008:administration & dosage; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D011687:Purines; D052999:Quinazolinones; D016159:Tumor Suppressor Protein p53; D000069283:Rituximab; C552946:idelalisib
keywords: 
  TP53
  ; B-cell prolymphocytic leukaemia; TP53 deletion; idelalisib; prolymphocytic leukaemia